Profile to raise $40 million for smart inhaler:
This article was originally published in Clinica
Executive Summary
Profile Therapeutics plans to raise £25.5 million ($40 million) on the London Stock Exchange. The Bognor Regis, Sussex-based company is developing inhaled drug delivery systems, based around its Adaptive Aerosol Delivery technology, which produces reproducible and precise doses by adapting to patients' breathing patterns. The company, which began as an inhaler distributor in 1977, launched its first product, the HaloLite system, in 1998. Its present turnover is around £10 million and the flotation, due for March 31, values the company at £81 million.